Imagenetix’s (OTC-BB: IAGX) Celadrin(R) Represents Massive Opportunity

Imagenetix, Inc. (OTC-BB: IAGX), a leading provider of nutraceuticals to several key end-markets, similar to companies like Gamma Pharmaceuticals (PINK:GMPM) and Natural Alternatives International, Inc. (NASDAQ:NAII), offers investors an excellent opportunity to profit from one of the hottest joint relief drugs on the market – Celadrin®.

According to the Arthritis Foundation, some 46 million Americans alone are affected by arthritis or other chronic joint symptoms, while arthritis is second leading cause of work disability among Americans. And with these patients making some 39 million physician visits, the estimated economic cost is more than $128 billion annually in the U.S.

Celadrin Offers Unique Relief to Joint Pain

Imagenetix has successfully developed an all natural Joint Health compound (Celadrin®) designed to improve joint mobility and replenish joint health. The compound was formulated through a proprietary process of esterifying oils, containing a mixture of fatty acids and carbons that have been scientifically aligned, enabling maximum joint restoration.

Patients taking Celadrin® showed improvement in joint movement and health in clinical studies. The compound is designed to enhance cell membranes, which serve as fluid reserves that provide valuable cushion for joints, by generating increased lubrication. Replenishing these damaged cells enables patients suffering from joint pain to experience greater joint support and flexibility.

Celadrin® conducted a double blind clinical trial that demonstrated strong efficacy compared to comparable products on the market with no side effects. Studies have shown 100% of osteoarthritis patients subject to a double blind study had experienced significant improvement as soon as 30 minutes, and that additional benefits were observed in the 30 days following. Moreover, these results gained considerable recognition after being published in the Journal of Rheumatology.

Celadrin® Launches Huge Expansion Push

Aggressive strategies for market penetration have been implemented, enabling Celadrin® to jockey for position in the market alongside existing drugs like Glucosamine and Chondroitin. Celadrin® extra soft gels can already be purchased at the nations leading drug chain, #1 and #2 supermarket stores, and the #1 club warehouse store in the U.S.

The strategy also involves extending the broadcast of its successful 15-30 sec television commercials to reach national audiences through cable networks. Beginning August 10th, viewers can watch commercials on networks like FOX News, CNN, USA and Hallmark. The television spots will highlight Celadrin® as a drug that offers “6x Faster and More Effective” results compared to products like Glucosamine and Chondroitin in supporting joint health.

A Well-Capitalized Company Poised to Profit

Imagenetix holds a strong financial position that will provide the company with necessary resources to accomplish its corporate and clinical goals. And with a current ratio of 3.75 and debt-to-equity of just 0.33, the company is in a strong financial position to reach its corporate, marketing and product development goals moving forward.